NCT03082768View on ClinicalTrials.gov

Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 3, 2017

Primary Completion Date

March 1, 2018

Study Completion Date

March 1, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

[18F]MNI-968

Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.

Trial Locations (1)

06510

Molecular NeuroImaging, LLC, New Haven

Sponsors
All Listed Sponsors
lead

Molecular NeuroImaging

OTHER